Secukinumab Doubles Remission Rate in Polymyalgia Rheumatica

The REPLENISH trial finds secukinumab doubles the remission rate and significantly lowers steroid use in relapsing polymyalgia rheumatica.
Medscape Medical News

Source link : https://www.medscape.com/viewarticle/secukinumab-achieves-doubling-remission-rate-and-2026a100061z?src=rss

Author :

Publish date : 2026-02-26 09:16:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
						1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31

Secukinumab Doubles Remission Rate in Polymyalgia Rheumatica

Store Peanut Products Effective for Desensitization in Kids?

Treating Cancer by Molecular Footprint, Not Organ

Related Posts

Can Romiplostim Reduce Chemo Disruptions in GI Cancer?

Worcester woman living with endometriosis plans concert to ‘give back’

Adrenaline Fails to Reverse Histamine-Induced Hypotension

COVID Shots in Pregnancy Protect Infants’ First 6 Months

Type 1 Diabetes Linked to Threefold Increase in Dementia Risk

When a Trip to the Hair Salon Ends in the Emergency Room

Can Romiplostim Reduce Chemo Disruptions in GI Cancer?

Worcester woman living with endometriosis plans concert to ‘give back’

Adrenaline Fails to Reverse Histamine-Induced Hypotension

COVID Shots in Pregnancy Protect Infants’ First 6 Months

Type 1 Diabetes Linked to Threefold Increase in Dementia Risk

When a Trip to the Hair Salon Ends in the Emergency Room

FDA OKs First Drug for Liver Disease-Related Pruritus

Alzheimer’s Gene Carriers With Higher Meat Intake Had Lower Dementia Risk

Categories

Archives